The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal

摘要: The cost-effectiveness of treating mild-to-moderate hypertension (diastolic blood pressures, 90-114 mmHg) was evaluated using the latest available information on both costs and benefits. net health care lifelong treatment for hypertension, at a 5% discount rate, ranged from 1491 pounds to 2752 in men 1568 2850 women New Zealand 1988 (1.00 = $NZ 2.81). These figures take into account savings arising stroke prevention. benefits, measured quality-adjusted life years (QALYs) discounted 5%, from--2 days (a negative effect treatment) 64 from--18 35 women. antihypertensive therapy (excluding categories patients whom ratio undefined due QALYs) 11,058 63,760 per QALY gained 22,060 194,989 Treatment more cost-effective than women, older age groups higher levels pretreatment diastolic pressure. ratios were highly sensitive rate used (with majority being 10% rate) regimen (diuretic monotherapy most cost-effective, followed by beta-blockers, then angiotensin-converting enzyme inhibitors), as well assumptions made about impact medication side effects patient quality life. results call re-examination resource allocation point need make assessments alternative, non-pharmacological approaches